Clinical trials: Histological Response
Sarcoma
Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma
The purpose of this study is to determine the overall best tumor response rate to dacarbazine given until disease progression as assessed by RECIST criteria, CT and clinical exams in patients with metastatic sarcomas.
- Trial name
- NCT00802880
- Testing
- Dacarbazine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Washington University School of Medicine
Multiple Myeloma, Amyloidosis
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
This is a phase II interventional study evaluating the use of minimal residual disease by next generation sequencing to defer autologous hematopoietic stem cell transplantation (AHCT) in patients with newly diagnosed multiple…
- Trial name
- NCT04991103
- Testing
- DaraVRD/DaraVCD
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Alabama at Birmingham
Mantle Cell Lymphoma (MCL)
Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma
Mantle Cell Lymphoma (MCL) is a form of Non-Hodgkin Lymphoma (NHL - cancer of the lymphatic system in blood) where cells from outer edge of the lymph nodes, called mantle zone become cancerous.
- Trial name
- NCT04477486
- Testing
- Ibrutinib, Venetoclax
- Where
- 12 sites in Japan
- Volunteers
- 13 people
- Sponsor
- AbbVie
AL Amyloidosis
Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis
This will be a systematic, combined, prospective assessment of the novel echographic, CMR, and PET imaging tools in newly-diagnosed patients with cardiac AL amyloidosis at baseline and after treatment.
- Trial name
- NCT04392960
- Testing
- [18F]Florbetaben
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Leukemia
Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Trial name
- NCT00045422
- Testing
- recombinant interferon alfa, imatinib mesylate
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma
A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer
This phase I/II trial studies how well PDS0101 alone or in combination with pembrolizumab works to shrink tumor in patients with human papillomavirus-associated oropharynx cancer that has spread to nearby tissue or lymph nodes…
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally Advanced Oropharyngeal Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Trial name
- NCT05232851
- Testing
- Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Pembrolizumab, Computed Tomography
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Lymphoma, Diffuse Large Cell
Genetic Determinations for Side Effects and Response Rate for Patients Receiving Chemotherapy With Diffuse Large Cell Lymphoma
The purpose of this study is to determine whether people have genes that make them more likely to respond to chemotherapy and/or have side effects from chemotherapy for diffuse large cell lymphoma.
- Trial name
- NCT00590941
- Testing
- Blood draw
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Washington University School of Medicine
Lymphoma, Large B-Cell, Diffuse
Identification Predictive Markers of Immunochemotherapy Response to the Primary Cutaneous Diffuse Large B Cell Lymphoma
The study is performed on a single-center retrospective cohort of 32 patients LBC-TJ treated with R-chemotherapy for which data collection was carried out in homogeneous and prospectively followed according to international…
- Trial name
- PROTEOM (NCT04183569)
- Testing
- Sequencing RNA.
- Where
- France
- Volunteers
- 32 people
- Sponsor
- University Hospital, Bordeaux
Melanoma
Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab
This study is a retrospective cohort study. A database will be created from the data available of all patients that have participate in the named patient program for pembrolizumab in the Netherlands.
- Trial name
- NCT02600169
- Testing
- Pemprolizumab
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- University Medical Center Groningen
Melanoma Stage III or IV
Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection
Dendritic cells (DCs) are the professional antigen-presenting cells of the immune system. As such they are currently used in clinical vaccination protocols in cancer patients, and both immunological and clinical responses have…
- Trial name
- NCT00243594
- Testing
- Peptide-pulsed dendritic cells
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Radboud University Medical Center
Diffuse Large B Cell Lymphoma
Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma
In Europe diffuse large B-cell lymphoma (DLBCL) is a rare disease whereas in Italy it is not. Approximately 40% of DLBCL patients has refractory disease or will relapse after initial response.
- Trial name
- NCT03797170
- Testing
- Gut microbiota samples
- Where
- 2 sites in Italy
- Volunteers
- 50 people
- Sponsor
- University of Bologna
HIV, AIDS
HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT
Kaposi's sarcoma (KS)is the commonest malignancy associated with HIV/AIDS. Therapy for this cancer, which causes substantial morbidity, is suboptimal in resource poor settings.
- Conditions
- HIV, AIDS, Kaposi's Sarcoma, Human Herpesvirus 8
- Trial name
- KAART (NCT00380770)
- Testing
- Generic HAART Triomune : d4T, 3TC, NVP, Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
- Where
- South Africa
- Volunteers
- 112 people
- Sponsor
- University of KwaZulu
Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia
Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
The purpose of this trial is to evaluate a CMV vaccine given to related donor/recipient pairs (donors prior to peripheral blood stem cell donation and CMV-seropositive recipients just before and after transplantation) and…
- Conditions
- Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Hodgkin's Lymphoma
- Trial name
- NCT00285259
- Testing
- VCL-CB01, Phosphate-buffered Saline (PBS)
- Where
- 22 sites in United States
- Volunteers
- 112 people
- Sponsor
- Astellas Pharma Inc
Breast Neoplasms, Breast Cancer
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early…
- Conditions
- Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma
- Trial name
- I-SPY (NCT01042379)
- Testing
- Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin
- Where
- 42 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- QuantumLeap Healthcare Collaborative
Non-Hodgkin's Lymphoma
Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma
In previous studies, the investigators found that in patients with Hodgkin's lymphoma (HL) treated with ABVD (adriamycin, bleomycin, vinblastine and decarbazine) the absence of alopecia may predict for a poor response to…
- Trial name
- NCT00969462
- Testing
- Doxorubicin
- Where
- Israel
- Volunteers
- 18 people
- Sponsor
- Meir Medical Center
Lymphoma, Nonneoplastic Condition
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00822120
- Testing
- bleomycin sulfate, filgrastim, ABVD regimen
- Where
- 423 sites in United States
- Volunteers
- 371 people
- Sponsor
- SWOG Cancer Research Network
HNSCC, DNA Damage
Predictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell Carcinoma
Nivolumab is FDA-approved for the treatment of patients with recurrent/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC). HNSCC whose disease has progressed within 6 months after platinum-based chemotherapy.
- Conditions
- HNSCC, DNA Damage, DNA Double Strand Break
- Trial name
- NCT03652142
- Testing
- Biomarker Research, Nivolumab
- Where
- Greece
- Volunteers
- 50 people
- Sponsor
- Attikon Hospital
Malignant Melanoma, Metastatic
Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma
The study is an open-label, single arm single Center Phase II study to evaluate the safety and efficacy of the combination of Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF, Leukine) and Ipilimumab (Yervoy) as therapy…
- Trial name
- GIPI (NCT01363206)
- Testing
- Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), Ipilimumab
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Lynn E. Spitler, MD
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
This study is to determine the response to acalabrutinib in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- Trial name
- NCT02337829
- Testing
- Acalabrutinib (Arm A), Acalabrutinib (Arm B)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Acerta Pharma BV
Locally Advanced or Metastatic Solid Tumours
A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer
This open labelled first in human dose phase 1/2a study is designed to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO and bempegaldesleukin (NKTR-214) immunotherapy in patients with…
- Trial name
- DIRECT-01 (NCT03548467)
- Testing
- VB10.NEO, Bempegaldesleukin
- Where
- 6 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Nykode Therapeutics ASA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.